The occurrence of a functional intracellular renin-angiotensin system (RAS) has emerged as a new paradigm. Recently, we and others demonstrated intracellular synthesis of ANG II in cardiac myocytes and vascular smooth muscle cells, which was dramatically stimulated in high glucose conditions. Cardiac fibroblasts significantly contribute to diabetes induced diastolic dysfunction. The objective of the present study was to determine the existence of the intracellular RAS in cardiac fibroblasts and role in extracellular matrix deposition. Neonatal rat ventricular fibroblasts were serum starved and exposed to isoproterenol or high glucose, in the absence or presence of candesartan that was used to prevent receptor mediated uptake of ANG II.
INTRODUCTION
Cardiac fibroblasts constitute one of the major cell types contributing to structural and functional properties of the heart (10). Cardiac fibroblasts produce extracellular matrix and secret growth factors and cytokines that are involved in the maintenance of myocardial function (23). There is a direct association between heart failure and cardiac fibroblast proliferation and deposition of extracellular matrix (8). Cardiac fibroblasts also interact dynamically with cardiac myocytes through mechanical, chemical, and electrical signals (5) . ANG II is an important factor that induces cardiac myocyte hypertrophy, fibroblast proliferation, and collagen deposition. ANG II is produced by both types of cells; and thus, functions as an autocrine/paracrine factor in the heart (16, 28, 40) .
Recently, others and we have described an intracrine role of ANG II in several cell types (3, 4, 13, 15, 20, 25 ). An intracrine mechanism supports the role of ANG II, acting from inside the cell, without binding to the plasma membrane AT 1 receptor. For intracrine actions, ANG II should be either generated intracellularly or internalized by the cells. Local ANG II is presumed to be synthesized in the interstitial space from secreted AGT, through the actions of renin and angiotensin converting enzyme (ACE). We recently reported that neonatal rat ventricular myocytes (NRVM) synthesize ANG II intracellularly; however, distribution of ANG II (intracellular or extracellular) is dependent on the nature of the activating stimulus (45). High glucose induced ANG II is completely retained intracellularly and translocated to the nucleus, while isoproterenol stimulated ANG II is largely secreted. The nature of the stimulus also determined the enzymes involved, chymase in high glucose and ACE in isoproterenol-induced ANG II synthesis (45).
ANG II has a significant role in diabetes induced organ damage (12). In hyperglycemia, circulating ANG II levels are reduced, indicating that locally produced tissue ANG II is critically important (19) . Intracellular retention of ANG II by cardiac myocytes, in high glucose conditions, suggests that an intracrine mechanism might play a major role in diabetes induced cardiac dysfunction (25). Because of ACE-independent synthesis and AT 1 -independent effects of intracellular ANG II, angiotensin receptor antagonists (ARBs) and ACE inhibitors would not block the intracellular reninangiotensin system (RAS) of cardiac myocytes. Cardiac fibroblasts also express components of the RAS and contribute to the cardiac ANG II pool (40). However, the site of synthesis and distribution of ANG II in cardiac fibroblasts and contribution of these cells to extracellular ANG II, for autocrine/paracrine actions, are not known. Given the therapeutic benefits of ARBs and ACE inhibitors, there is likelihood of cardiac fibroblasts being the major source of extracellular ANG II in diabetic conditions. In the case of intracellular synthesis of ANG II in cardiac fibroblasts, it would be important to determine the role, if any, of intracrine mechanisms in extracellular matrix deposition.
Here, we demonstrate that cardiac fibroblasts synthesize ANG II intracellularly and extracellularly. Intracellular ANG II upregulates transforming growth factor-β (TGF-β) and collagen-1 production by cardiac fibroblasts. This study identifies significant differences in the regulation of the intracellular RAS by high glucose, between cardiac fibroblasts and myocytes.
METHODS
Cell culture. Neonatal rat ventricular fibroblasts were isolated from hearts of 0 to 2 day-old Sprague Dawley rat pups, by enzymatic dispersion of the ventricular tissue and differential plating, as previously described (40). Non-myocytes were maintained for 2 days in DMEM:M199::3:1 medium containing 5.5 mM glucose and supplemented with 10% horse serum, 5% fetal calf serum, 0.1 mM ascorbic acid, 1 µg/ml transferrin, 10 ng/ml sodium selenite, 100 U/ml penicillin and 100 µg/ml streptomycin. Confluent cells were passaged two times to yield cultures that were almost exclusively fibroblasts (> 99 % purity), as previously reported (27, 41). Culture medium was changed to serumfree for 24 h and cells were exposed to isoproterenol (10 μM) or high glucose (medium containing 12.5, 17, and 25 mM glucose) for 24, 48, and 72 h. To correct for hyperosmolarity, equivalent amounts of mannitol were added to control sets of cells. To exclude internalization of ANG II through AT 1 receptor mediated endocytosis, candesartan (1 μM, AstraZeneca) was added to the culture medium 24 h before and during exposure to isoproterenol or high glucose.
ANG II measurement. ANG II was measured in the cell lysates and culture medium by a quantitative, competitive ELISA, using a specific anti-ANG II antibody (Peninsula Labs), as previously described (3) . Briefly, cells were washed with PBS and scraped in ice-cold 1 M acetic acid, containing a protease inhibitor cocktail (Sigma), and lysed by sonication (29, 42). The lysate was sedimented at 20,000 x g for 10 min and the supernatant was dried in a vacufuge, followed by reconstitution in 1% acetic acid.
The samples were applied to a conditioned DSC-18 column (Supelco), washed, and eluted with methanol. The eluted samples were dried and reconstituted in PBS for ELISA. For extracellular Ang II, culture medium was collected and protease inhibitor cocktail added before filtering through Amicon Ultra-15 filters. The filtered medium was applied to DSC-18 columns and Ang II eluted, as described for the cell lysate. Using this procedure, we have obtained more than 90% recovery of exogenously added Ang II. Western analysis. Based on the time course of ANG II synthesis, cardiac fibroblasts were exposed to high glucose (25 mM) or isoproterenol (10 µM) for 24 h, as described above. Equal amounts of cell lysate or culture medium proteins (30 µg) were separated on 4-20 % SDS-polyacrylamide gels and transferred to nitrocellulose membranes as previously described (45). Blots were probed with anti-angiotensinogen (Swant), anti-renin (Swant and Dr. Tadashi Inagami, Vanderbilt University), antichymase (Abcam), or anti-ACE-1 (Abcam) antibody. Equal protein loading was confirmed by Anti-GAPDH or anti-actin antibody for cell lysates and coomassie staining for culture medium. Protein bands were detected using anti-Mouse and anti-Rabbit secondary antibodies labeled with infrared dye 680/800 and Odyssey Infrared Imaging System (LI-COR, Biosciences).
Enzyme inhibition.
To identify the enzymes involved in ANG II synthesis, specific inhibitors were added to the culture medium at the time of exposure to isoproterenol or high glucose. The following inhibitors were used: aliskiren (renin inhibitor from Novartis, 1 -50 μM); benazeprilat (ACE inhibitor, 0.1 -10 μM); and chymostatin (chymase inhibitor, 1 -100 μM).
Confocal immunofluorescence microscopy. Cardiac fibroblasts grown on twowell, collagen coated chamber slides, at a density of 0.3 x 10 5 cells/well, were exposed to isoproterenol or high glucose and immunostaining performed as described previously (45). Specificity of the anti-ANG II antibody was confirmed by pre-adsorption with 10-fold molar excess of synthetic ANG II. Images were acquired through z-axis scanning with a X60 objective on a 3-D confocal fluorescence microscope (Olympus Fluoview 300) and analyzed by three-dimensional rendering using the Volocity 4 software package (Improvision). To study internalization of ANG II by cardiac fibroblasts Alexa-488 labeled ANG II (50 nM, Molecular Probes) was added to the culture medium at the time of exposure to isoproterenol and high glucose. After 24 h, cells were washed with PBS and analyzed for the presence of labeled ANG II by confocal microscopy, as described previously (45).
TGF-β and collagen-1 analysis. Cardiac fibroblasts were grown in high glucose (25 mM) containing medium in the absence or presence of candesartan (1 µM), aliskiren (10 µM), or benazeprilat (10 µM) for 24 h. In a control experiment, ANG II (100 nM) was added to the culture medium in the absence or presence of candesartan. TGF-β and collagen-1 were analyzed in cell lysates and culture medium by Western analysis, using anti-TGF-β (Santa Cruz) and anti-collagen-1 (Santa Cruz) antibody.
Statistical analysis.
Values are mean ± SE. ANOVA with Tukey's post hoc test was used for statistical analysis. P < 0.05 was considered statistically significant.
RESULTS
Our recent demonstration of intracellular synthesis and intracrine effects of ANG II in cardiac myocytes has revealed a novel, intracellular aspect of the RAS that might have a significant role in cardiac pathophysiology (45). Cardiac fibroblasts represent the major non-muscle cells in the heart, which synthesize and respond to ANG II, with significant implications in cardiac pathophysiology. Here, we present evidence of an intracellular RAS in cardiac fibroblasts, which differs significantly from that reported in cardiac myocytes.
To demonstrate de novo synthesis of ANG II, cardiac fibroblasts were grown in serum free medium and the RAS was stimulated with high glucose or isoproterenol. The AT 1 receptor antagonist candesartan was added to the culture medium to prevent cellular uptake of ANG II, which was confirmed by adding Alexa fluor 488-labeled ANG II (Supplemental data). Under these conditions, an increase in ANG II levels in the cell lysate was considered to be due to intracellular synthesis. An increase in culture medium ANG II could be due to extracellular synthesis or release of intracellularly synthesized ANG II.
Isoproterenol and high glucose increase both intracellular and extracellular synthesis of ANG II. Exposure of cardiac fibroblasts to isoproterenol (10 µM) for 24 h resulted in an increase in ANG II levels in the cell lysate (41 ± 6 %) and culture medium (139 ± 8 %) (Fig 1, A and B) . Similarly, high glucose also increased ANG II levels in both cell lysate and the culture medium (59 ± 4 and 92 ± 4 %, respectively) ( Fig. 1,C and D) .
Significantly increased intracellular levels of ANG II were also observed in the presence of candesartan, following exposure to isoproterenol and high glucose (73 ± 8 and 80 ± 7%, respectively), confirming intracellular synthesis, rather than uptake. Mannitol, used as a control for osmolarity, did not have any significant effect on ANG II concentrations.
The increase in extracellular ANG II in response to high glucose was in contrast to cardiac myocytes where only intracellular levels were elevated (45). anti-ANG II antibody, followed by detection with confocal fluorescence microscopy. A punctate cytoplasmic staining was observed, in both isoproterenol and high glucose stimulated cells (Fig. 3) . Three-dimensional analysis using Volocity software demonstrated significant perinuclear staining with small amounts of ANG II inside the nucleus.
Increase in intracellular renin levels following exposure to isoproterenol and high
glucose. Intracellular generation of ANG II would require the presence of RAS components intracellularly and regulation by the synthesis promoting stimuli. To determine the levels of AGT, renin, ACE, and chymase, cell lysate and the culture medium of cardiac fibroblasts was subjected to Western blot analysis using respective antibodies. Renin protein levels were significantly increased in both the cell lysate and culture medium following exposure to high glucose and isoproterenol (Figs. 4 and 5, respectively), corroborating the observed increase in ANG II levels. These results were confirmed using a second, well-characterized, renin antibody obtained from Dr. Tadashi
Inagami (data not shown). AGT levels were significantly increased only in the culture medium, while ACE and chymase levels in the cell lysate were not affected. The latter two enzymes were not detectable in the medium (data not shown). These results suggested that the renin-catalyzed rate limiting step of AGT to ANG I conversion controlled intracellular generation of ANG II.
Enzymes involved in cardiac fibroblast ANG II synthesis.
To further elucidate the synthesis pathway, we measured ANG II levels in cells exposed to isoproterenol or high glucose, in the presence of specific inhibitors of renin (aliskiren), ACE (benazeprilat), and chymase (chymostatin). Aliskiren, a very potent and specific inhibitor of human renin (IC 50 = 0.6 nM) has also been shown to inhibit rat renin (IC 50 = 80 nM) (52, 53).
The inhibitors need to enter the cells to block intracellular ANG II synthesis. Cardiac myocytes effectively internalize aliskiren, resulting in intracellular concentrations that are about 3-fold higher than those in the medium, after 24 and 48 h following addition (data not shown). Benazeprilat is at the top of the relative rank order of tissue potency of the ACE inhibitors, suggesting efficient membrane permeability (17) . Chymostatin was solubilized in DMSO, which enhances cell penetration of the drug (55). Thus, the above inhibitors were suitable to study the enzymes involved in intracellular ANG II synthesis.
As shown in Fig. 6 , both isoproterenol and high glucose induced ANG II generation was completely inhibited by aliskiren and benazeprilat, in the cell lysate as well as culture medium. Chymostatin did not have any effect on ANG II generation in cardiac fibroblasts (data not shown), unlike NRVM where intracellular synthesis was catalyzed by chymase (45). The observed small effect of renin and ACE inhibitors on basal Ang II levels is likely due to the very low level of Ang II forming activity in unstimulated cells.
Intracellular ANG II enhances TGF-β and collagen-1 production in cardiac fibroblasts.
Intracellular ANG II has biological effects in several cells, such as cardiac myocytes, vascular smooth muscle (VSMC) and Chinese hamster ovary cells (3, 4, 18) . To determine if the increase in intracellular ANG II levels has physiological significance in cardiac fibroblasts, we determined TGF-β and collagen-1 production in cells exposed to high glucose. To exclude the effects of extracellular ANG II, candesartan was added to the culture medium. To confirm that any change in TGF-β or collagen is due to increased intracellular ANG II, not due to high glucose, ANG II synthesis was blocked by aliskiren and benazeprilat. As shown in Fig. 7 , candesartan inhibited collagen-1 production only partially in both the cell lysate and culture medium. In a control experiment, extracellular ANG II-induced collagen-1 synthesis was completely inhibited by candesartan. In contrast, aliskiren and benazeprilat, which block ANG II generation both extra-and intracellularly, completely prevented high glucose induced collagen-1 synthesis. A similar effect of these agents on TGF-β production was also observed ( Earlier, others and we had reported that intracellular ANG II has multiple biological effects in several types of cells (3, 4, 13, 15, 20, 25) . It is generally believed that the local RAS has a more significant role than the circulating system in cardiac pathophysiology (36). Significantly, it has been suggested that intracellular ANG II might be a major regulator of the local RAS (24, 37). Considering the pathophysiological significance of the intracellular RAS, as discussed in recent reviews (25, 35, 38), it was important to investigate it in major cell types.
Other than cardiac myocytes, fibroblasts are the major cells of heart that are RAS positive and involved in cardiac structure and function (5, 7, 40 The presence of ACE in the intracellular milieu and participation in ANG II generation antagonists, in the treatment of diabetic cardiac fibrosis. In fact, it could be inferred from a recent meta-analysis of clinical trials that the cardiovascular events that are largely blood pressure-dependent, such as stroke, are benefitted similarly by ACE inhibitors and ARBs; however, the events that involve tissue remodeling, such as coronary heart disease, may benefit more from an ACE inhibitor than ARBs (48).
Clinical perspective
With an increasing prevalence of diabetes, it is imperative to enhance our understanding of the pathology of myocardial fibrosis, to develop better pharmacological interventions. Inhibition of the RAS by ARBs and ACE inhibitors has provided significant therapeutic benefits; however, pharmacological outcomes may be even more impressive from complete inhibition of the RAS (47, 51). The difference could be related to the intracellular RAS, which may not be amenable to current therapies, as depicted in Fig. 9 . Cardiac myocytes and fibroblasts respond differently to high glucose conditions, the former robustly activating only the intracellular RAS, while the latter contributes to both intra-and extracellular ANG II generation. ARBs only inhibit effects of extracellular ANG II, as is evident from this and our previous studies (3, 4) and ACE inhibitors would block ANG II synthesis only in cardiac fibroblasts. These observations suggest that ACE inhibitors or ARBs when used alone might not inhibit the cardiac RAS completely, in diabetic conditions. The beneficial effects of ACE inhibition in AT 1a knockout mice, on left ventricular remodeling following myocardial infarction, may be related to inhibition of intracellular ANG II synthesis in cardiac fibroblasts (54). The current study provides mechanistic data on the cardiac RAS at the cellular level, and may lead to more appropriate therapeutic regimens in the treatment of cardiac diseases.
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